Leflunomide 20 mg: Patients in study shall receive loading dose of Tab Leflunomide 100 mg daily for 3 days followed by 20 mg daily orally. Leflunomide will be given till day 180 + post haploidentical transplant or till patient is on systemic immunosuppression.
Study summary
Patients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these patients and to assess its safety.
The main questions it aims to answer are -
1. Does leflunomide prevent cytomegalovirus (CMV) related organ damage?
2. Does leflunomide prevent a rise in cytomegalovirus (CMV) copy number to more than 2000 copies/ml?
3. Does leflunomide prevent the need to start pre-emptive therapy for cytomegalovirus (CMV)?
4. Is it safe to use in bone marrow transplant ( BMT) patients?
5. Does leflunomide prevent other viral reactivations - like Adeno virus and BK virus?
6. Does leflunomide affect the risk of acute graft-versus-host disease ( acute GVHD) after bone marrow transplant (BMT)?
What medicine will the patients receive? Patients in study shall receive loading dose of Tab. Leflunomide 100 mg daily for 3 days followed by 20 mg daily orally. Leflunomide will be given till day +180 post transplant or till patient is on immunosuppressant medicines.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Males or females undergoing Haplo-identical haematopoetic stem cell transplant.
2. Age ≥18yrs on the day of signing informed consent
3. Undetectable CMV from plasma sample in preceding 7 days
4. Patient who has WBC engraftment (ANC\>=500/cumm for 3 or more consecutive days).
5. Within 7 days of WBC engraftment
6. Adequate liver functions (ALT / AST less than 5 times upper limit of normal and Bilirubin \<=3 times upper limit of normal) at time of starting leflunomide
7. Understands the study procedures, alternative treatment available, and risks involved with the study, and voluntarily agree to participate by giving written informed consent.
Exclusion Criteria:
1. Known hypersensitivity to Leflunomide
2. History of clinically significant CMV reactivation in past 1 year
3. Patient is receiving/has received drug known to have anti CMV activity within in last 7 days \[Ganciclovir, valganciclovir, foscarnet, letermovir, acyclovir (at doses \>=3200 mg PO per day or \>=25 mg/kg IV per day), valacyclovir (at doses \&\>=3000 mg PO per day)\]
4. Inadequate renal function (creatinine clearance \<=30 ml/min)
5. Chronic active hepatitis B (HBsAg+ or any HBV DNA+), hepatitis C, or/and HIV
6. Any psychiatric condition that might limit the ability of the patient to comply with the protocol
Primary outcome measure(s)
Number of participants with clinically significant cytomegalovirus (CMV) infection — Through Day +180 post hematopoietic stem cell transplantation (HSCT). Number of participants with clinically significant cytomegalovirus (CMV) infection through Day +180 after hematopoietic stem cell transplantation (HSCT). Clinically significant CMV infection is defined as the occurrence of one or more of the following:
Cytomegalovirus (CMV) end-organ disease; Cytomegalovirus (CMV) viremia ≥2,000 copies/mL measured by the central laboratory; or Initiation of pre-emptive anti-CMV therapy at the investigator's discretion.
Trial sites (3)
Facility
City
Region
Status
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) Tata Memorial Centre
Navi Mumbai
Maharashtra
Recruiting
Advanced Centre for Treatment, Research and Education in Cancer
Navi Mumbai
Maharashtra
Not Yet Recruiting
Advanced Centre for Treatment, Research and Education in Cancer
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.